T
Theo van der Kwast
Researcher at Erasmus University Medical Center
Publications - 5
Citations - 1467
Theo van der Kwast is an academic researcher from Erasmus University Medical Center. The author has contributed to research in topics: Prostate cancer & Surgical margin. The author has an hindex of 3, co-authored 5 publications receiving 1272 citations.
Papers
More filters
Journal ArticleDOI
Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up
Fritz H. Schröder,Jonas Hugosson,Monique J. Roobol,Teuvo L.J. Tammela,Marco Zappa,Vera Nelen,Maciej Kwiatkowski,Marcos Lujan,Liisa Määttänen,Hans Lilja,Louis Denis,Franz Recker,Alvaro Paez,Chris H. Bangma,Sigrid Carlsson,Sigrid Carlsson,Donella Puliti,Arnauld Villers,Xavier Rebillard,Matti Hakama,Ulf-Håkan Stenman,Paula Kujala,Kimmo Taari,Gunnar Aus,Andreas R. Huber,Theo van der Kwast,Ron H.N. van Schaik,Harry J. de Koning,Sue Moss,Anssi Auvinen +29 more
TL;DR: In this update the ERSPC confirms a substantial reduction in prostate cancer mortality attributable to testing of PSA, with a substantially increased absolute effect at 13 years compared with findings after 9 and 11 years.
Journal ArticleDOI
A BRCA1/2 mutation, high breast density and prominent pushing margins of a tumor independently contribute to a frequent false-negative mammography.
Madeleine M. A. Tilanus-Linthorst,L.C. Verhoog,Inge-Marie Obdeijn,Karina Bartels,Marian B. E. Menke-Pluymers,Alexander M.M. Eggermont,Jan G. M. Klijn,Hanne Meijers-Heijboer,Theo van der Kwast,Cecile T. M. Brekelmans +9 more
TL;DR: MRI was carried out in 12 carriers, had 100% sensitivity and detected 5 cancers, still occult at physical examination and mammography, which suggests additional methods like MRI may be needed for early BC detection in mutation carriers.
Journal ArticleDOI
Reply from Authors re: Michael Baum. Screening for Prostate Cancer: Can We Learn from the Mistakes of the Breast Screening Experience? Eur Urol 2013;64:540–1: Screening for Prostate Cancer: We Have Learned and Are Still Learning
Monique J. Roobol,Ries Kranse,Chris H. Bangma,Suzie J. Otto,Theo van der Kwast,Leonard P. Bokhorst,Harry J. de Koning,Fritz H. Schröder +7 more
TL;DR: The question in the introduction of the editorial, ‘‘Does screening for breast cancer improve LoL andorQoL?’’ was a resounding no and all cancer-screening trials must be reported using absolute numbers, numbers needed to screen to avoid a causespecific death, all-cause mortality, and some measure of QoL.
Should prostate tumor volume routinely be reported by the pathologist?: The prognostic value of tumor volume in prostate cancer
Tineke Wolters,Monique Roobol-Bouts,Pim J. van Leeuwen,Roderick C.N. van den Bergh,Robert F. Hoedemaeker,Geert J.H.L. van Leenders,Fritz H. Schröder,Theo van der Kwast +7 more
TL;DR: There seems to be little reason to routinely measure tumor volume in RP specimens, and tumor volume did not add prognostic value to routinely assessed pathological parameters, like tumor stage, Gleason score, seminal vesicle invasion and surgical margin status.
Should prostate tumor volume routinely be reported by the pathologist?: The prognostic value of tumor volume in prostate cancer [Moet het prostaattumorvolume standaard worden vermeld door de patholoog? De prognostische waarde van tumorvolume in prostaatkanker]
Tineke Wolters,Monique Roobol-Bouts,Pim J. van Leeuwen,Roderick C.N. van den Bergh,Robert F. Hoedemaeker,Geert J.H.L. van Leenders,Fritz H. Schröder,Theo van der Kwast +7 more
TL;DR: Tumor volume was measured in 344 totally embedded radical prostatectomy specimens of screen detected prostate cancer cases as mentioned in this paper, and tumor volume was predictive for biochemical and local progression, metastasis and mortality.